E10L1

E10L1 is an investigational exosome-based therapy being developed by Guangzhou Double Bioproducts (also known as Guangzhou Dabao Bioproducts). As an exosome therapy, it utilizes extracellular vesicles to deliver bioactive cargo—such as proteins, nucleic acids, or lipids—to target cells, potentially offering a more targeted and less immunogenic delivery method compared to traditional viral vectors. While specific molecular targets and therapeutic indications for E10L1 have not been publicly disclosed, it is part of the company's 'E10' pipeline, which is primarily focused on the development of advanced biologics for oncological indications.